Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary Adenomas

Recruiting now · Phase 1

Conditions studied: Pituitary Adenoma

In brief

The purpose of this research is to evaluate the diagnostic role and clinical efficacy of investigational FET-PET/MRI in detecting MRI-occult primary or residual/recurrent functional pituitary adenomas (PAs) and its influence on clinical and surgical decisions.

Key facts

Study ID

NCT07456878

Run by

Mayo Clinic

People needed

5

Starts

2026-01-08

Expected to finish

2026-12-01

Last updated by the study team

2026-03-09

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients 18 to 75 years of age with biochemically proven CD, Acromegaly, or tumor hyperprolactinemia as per current Endocrinology guidelines.
• Clinical DCE-MRI protocol that is negative or equivocal for identifiable tumor.
• Patient willing to have surgery if lesion found, or already scheduled for surgery and lesion identification would be helpful.
• Able to provide informed consent and be capable of completing the imaging protocols.
• Female subjects of childbearing potential (women of childbearing potential [WOCBP]) must have a negative urine pregnancy test ≤48 hours prior to the 18F-FET injection.

You may not qualify if…

• Patients with contraindications to MRI or PET scans.
• Patients with known allergies to contrast agents or other imaging-related materials.
• Patients with severe medical conditions that preclude participation in the study (e.g. inability to lie supine for 30-60 minutes).
• Patients with successful MRI localization of the adenoma.

Where it is running

• Mayo Clinic — Jacksonville, Florida, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.